

GLAXOSMITHKLINE - Novel Combo therapy (BRAF+MEK) filed in Europe – Potential New SoC for BRAF positive metastatic melanoma patients

https://marketpublishers.com/r/G869D445E74EN.html

Date: February 2013 Pages: 3 Price: US\$ 90.00 (Single User License) ID: G869D445E74EN

Abstracts

GSK announced the filing of its BRAF and MEK inhibitors– trametinib (MEK inhibitor) as monotherapy and in combination with dabrafenib (BRAF inhibitor) as combo therapy for the treatment of metastatic melanoma with a BRAF V600 mutation. The application has been submitted for accelerated assessment with the review time of 150 days. The accelerated assessment and early filing of the combination therapy is based on extraordinary efficacy shown in PhII study which doubled the response rate and PFS (9.5mo vs.5.6mo) compared to BRAF inhibitor monotherapy. The combination should become the new standard of care in melanoma patients with BRAF+ve mutation as besides better efficacy it also lowers the dermatological toxicity associated with monotherapy Zelboraf.



I would like to order

Product name: GLAXOSMITHKLINE - Novel Combo therapy (BRAF+MEK) filed in Europe – Potential New SoC for BRAF positive metastatic melanoma patients Product link: <u>https://marketpublishers.com/r/G869D445E74EN.html</u> Price: US\$ 90.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G869D445E74EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



GLAXOSMITHKLINE - Novel Combo therapy (BRAF+MEK) filed in Europe – Potential New SoC for BRAF positive metasta...